7 years treating AML
250 AML patients anually
Dr. Blachly's research focus is on genomics and gene transcription in leukemia and its relevance in experimental therapeutics. His work explores whether and how mutations and transcriptional attributes can be studied in the context of clinical trials to provide prognostic and predictive information relevant to novel anticancer therapies.
Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.
Terms of Use and Privacy Policy Newsroom About Donations Find an AML Specialist Newsletter Learn Connect
Copyright © 2022 HealthTree Foundation. All Rights Reserved.
The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811